According to Thomson Reuters, sell-side analysts are forecasting a harmony target price of $139.82 on company shares.
The appearance of Icahn on the circuit surprised the executives of Bristol-Myers too who were already dealing with the changes in the board and the repurchase of $2 billion in stocks as was negotiated with Jana Partners. Bristol-Myers Squibb Company highlighted its earnings failure in the latest quarter as it miss the Street's earnings consensus estimates of $0.67 by -$0.04. If Icahn does push for a sale, it would push the stock price up even higher. They are projecting Next Quarter growth of 0%. They now have a Dollars 66 price target on the stock. They now have a Dollars 58 price target on the stock. Bristol-Myers Squibb Company had a net margin of 22.94% and a return on equity of 31.39%. They now have a Dollars 47 price target on the stock. The company earned $5.24 billion during the quarter, compared to analysts' expectations of $5.14 billion. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and ten have issued a buy rating to the company's stock. Bristol-Myers Squibb Company got Upgrade on 19-Dec-16 where investment firm Jefferies Upgrade the stock from Hold to Buy. They now have a United States dollars 69 price target on the stock. Bristol-Myers Squibb Company presently has an average rating of Hold and a consensus price target of $62.72. They now have a United States dollars 67 price target on the stock. They now have a Dollars 70 price target on the stock. Canada Pension Plan Investment Board now owns 2,941,909 shares of the biopharmaceutical company's stock valued at $158,628,000 after buying an additional 1,307,141 shares in the last quarter. They now have a Dollars 90 price target on the stock. BlackRock Institutional Trust Company N.A. raised its position in shares of Bristol-Myers Squibb Company by 5.7% in the third quarter. They now have a United States dollars 65 price target on the stock. BlackRock Group LTD now owns 14,942,065 shares of the biopharmaceutical company's stock worth $805,676,000 after buying an additional 365,557 shares during the last quarter.
Bristol-Myers Squibb Company (NYSE:BMY)'s earnings per share has been growing at a 4.2 percent rate over the past 5 year when average revenue increase was noted as -1.8 percent.
While trading at volume below than average, Apple Inc.
Moving toward other technical indicators, stock is wondering in considerable region as it has 20 days moving average of 7.71% and struggles for 50 days moving average of buoyant run is -0.60%.
Jana and investors like Icahn making significant stock acquisitions adds fuel to the takeover rumors that BMS is a hot property on the takeover market. According to 21 analysts, Price Target for Bristol-Myers Squibb Company (NYSE:BMY) may hit a high of $68. Bristol-Myers Squibb Company's dividend payout ratio (DPR) is now 58.87%. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience.